Drug company will fund rare cancer treatment

Nursing Times.com | 2009-12-21

The manufacturer of a drug which could extend the lives of thousands of people suffering from a rare form of cancer has agreed to pay for further patient treatment as part of a cost-cutting scheme.

The company PharmaMar has announced it will meet the expense of the cancer drug, called trabectedin, if a patient needs it beyond a fifth cycle.

The decision by NICE means the lives of people suffering with advanced soft tissue sarcoma could be extended by at least three months.

Related Medical Tourism News
Focus Area
Free Call